XIV Eurasian Hematology-Oncology Congress - EHOC 2023
A

The Role of Luspatercept in Transfusion-Dependent Patients With Beta Thalassemia - A Case Discussion

By XIV Eurasian Hematology-Oncology Congress - EHOC 2023 FEATURING Anıl Tombak
By XIV Eurasian Hematology-Oncology Congress - EHOC 2023 FEATURING Anıl Tombak
26 views
February 13, 2024
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
42:10
Insights from 2023 ASH Annual Meeting

Highlights in Red Cell and Platelet Disorders From ASH 2023

Feat. M. Blinder
08:11
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "A Novel Beta Globin Frameshift Mutation Cau…

Feat. L. Bilston
13:57
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Pyruvate Kinase Activators - Targeting Red …

Feat. K. Kuo
18:15
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Updates in Cellular Therapy for Sickle Cell Disease and Beta-Thalass…

Feat. S. Peslak
10:22
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

State-of-the-Art in Managing Thalassemias

Feat. M. Cappellini
33:17
Indy Hematology Review

Managing Benign Hematology Disorders

Feat. C. Kessler
16:09
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Case-Based Discussion: Managing Non-Transfusion-Dependent Thalassemia

Feat. A. Taher
08:41
ASH 2022 Conference Coverage

ASH 2022 Long-Term Outcomes of Patients With TDT Followed Up to 8 Ye…

Feat. M. Walters
09:49
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Bu-Cy or Treosulfan-Flu-Thiotepa-Based Myeloablative Conditioning fo…

Feat. N. Bayram
33:24
Zahra Pakbaz

Current Approach to Sickle Cell Anemia: COVID & SCD, Genotypes, …

31:43
Suhag Parikh

Updates on Curative Therapies for Sickle Cell Disease: Allogeneic HS…

10:26
James Taylor

Forms of SCD: Sickle Cell Anemia, Hb SC Disease, Beta/Alpha-Thalasse…

25:01
Indy Hematology Review

Review of Emerging Therapies and Top Trials in Hematologic Malignanc…

Feat. R. Birhiray
23:18
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Curative Options for Hemoglobinopathies: Is MSD the SoC in Thalassem…

Feat. S. Corbacioglu
28:21
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - Benign Hematolgy - Analysis of Top Trials

Feat. P. Harris
17:49
KU ASH 2019 Review: Current Updates in Hematologic Diseases

KU ASH 2019 Review on Benign Hematology: New FDA Approvals, 2nd-Line…

Feat. P. Harris
19:17
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Managing Late Complications in Beta Thalassemia: Thrombotic Disease,…

Feat. V. Huseynov
24:46
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on Non-Malignant Hematology: Mycophenolate for ITP, CTX0…

Feat. M. Thirman
13:05
KU ASH 2019 Review: Current Updates in Hematologic Diseases

KU ASH 2019 Review on Benign Hematology: Sutimlimab in CAD, Erythrof…

Feat. P. Harris
59:08
Vivien Sheehan

From Genomics to Biomarkers in Sickle Cell Disease: Can Genomics Reg…